(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer
$89,140R01FY2020CANIH
Icahn School Of Medicine At Mount Sinai, New York NY
Investigators
Linked publications, trials & patents
Paper 39112519Paper 38469801Paper 38295690Paper 37884500Paper 37774414Paper 37537299Paper 37379717Paper 37314393Paper 37141574Paper 36747009Paper 36737841Paper 36448571Paper 36300627Paper 35837138Paper 35412614Paper 35210568Paper 34520194Paper 34378936Paper 34131295Paper 34100597Paper 34087994Paper 33970635Paper 33750924Paper 33469207Paper 32128407Paper 31819273Paper 31145866Paper 30926792
Abstract
Project Summary This is an application for a Research Supplement to Promote Diversity in Health-Related Research (PA-18-906). The parent R01 project associated with this application is entitled ?(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer? supported by NCI (5R01CA230854-02). Brandon Dale is the diversity candidate. He is a US citizen of African-American descent and is currently an MD/PhD graduate student at Icahn School of Medicine at Mount Sinai, New York. The main goal of this study is to characterize a set of EZH2 degraders in triple-negative breast cancer cellular models.
View original record on NIH RePORTER →